11/26
01:14 pm
dwtx
Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight [Yahoo! Finance]
Low
Report
Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight [Yahoo! Finance]
11/6
08:45 am
dwtx
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
Medium
Report
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
10/8
12:19 pm
dwtx
Dogwood Therapeutics (NASDAQ:DWTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Dogwood Therapeutics (NASDAQ:DWTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/7
09:10 am
dwtx
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit [Yahoo! Finance]
Medium
Report
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit [Yahoo! Finance]
9/30
08:06 am
dwtx
Dogwood Therapeutics (NASDAQ:DWTX) had its price target raised by analysts at HC Wainwright from $10.00 to $12.00. They now have a "buy" rating on the stock.
Medium
Report
Dogwood Therapeutics (NASDAQ:DWTX) had its price target raised by analysts at HC Wainwright from $10.00 to $12.00. They now have a "buy" rating on the stock.
9/29
08:03 am
dwtx
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients [Y
High
Report
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients [Y
9/29
07:15 am
dwtx
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients
High
Report
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients